Trastuzumab Rezetecan

Overview

Trastuzumab rezetecan is a novel HER2-targeted antibody-drug conjugate (ADC) designed to deliver cytotoxic payload selectively to tumor cells overexpressing or amplifying the human epidermal growth factor receptor 2 (HER2), encoded by the Human epidermal growth factor receptor 2 (HER2) (ERBB2) gene. Like other HER2-directed ADCs, trastuzumab rezetecan consists of a trastuzumab-based monoclonal antibody backbone conjugated to a cytotoxic small molecule via a chemical linker, enabling targeted intracellular drug delivery upon receptor-mediated internalization. Its development reflects the broader therapeutic rationale of exploiting HER2 overexpression — a validated oncogenic driver across multiple tumor types including gastric, gastroesophageal junction (GEJ), colorectal, breast, head/neck, melanoma, and prostate tumors — to achieve tumor-selective cytotoxicity while limiting systemic toxicity.

HER2-directed ADCs have emerged as a cornerstone of precision oncology following the clinical success of ado-trastuzumab emtansine (T-DM1) and, more recently, trastuzumab deruxtecan (T-DXd). Trastuzumab rezetecan represents a next-generation entry in this class, distinguished by its specific linker-payload architecture. Its evaluation across HER2-expressing gastrointestinal malignancies positions it within an active area of unmet clinical need, particularly as optimal ADC sequencing strategies and resistance mechanisms in HER2-positive disease remain incompletely defined.

Recent Publications Focus

Recent work has focused on trastuzumab rezetecan as a HER2-targeted antibody-drug conjugate in advanced HER2-expressing malignancies. A multicenter, open-label phase I trial evaluated trastuzumab rezetecan in patients with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer, reflecting early clinical exploration of its activity across tumor types with HER2 expression 41779980Mar.

Several publications in the same period addressed trastuzumab deruxtecan, providing context for the broader HER2-targeted ADC landscape in which trastuzumab rezetecan is being studied. In HER2-positive metastatic breast cancer, real-world sequencing questions were examined for trastuzumab deruxtecan with and without prior trastuzumab emtansine exposure, highlighting uncertainty about optimal ADC sequencing 41980521Apr. In HER2-positive advanced gastric cancer, an exploratory analysis of EN-DEAVOR assessed the effect of prior immune checkpoint inhibitor treatment, including nivolumab, on subsequent trastuzumab deruxtecan outcomes and safety 41789591Mar.

Other recent reports have examined practical and translational issues relevant to HER2-targeted ADC use. A hospital in-use stability study found that reconstituted trastuzumab deruxtecan maintained key physical, chemical, and affinity characteristics for up to 4 weeks under appropriate storage conditions, extending beyond the routine 48-hour discard window 42009233Apr. Separately, pharmacovigilance analyses compared adverse event profiles of trastuzumab emtansine and trastuzumab deruxtecan using JADER and FAERS databases, underscoring ongoing efforts to characterize safety across HER2-directed ADCs 42379740Jun.

Additional publications discussed trastuzumab deruxtecan in specific clinical settings and trial interpretation. A commentary on neoadjuvant use in high-risk HER2-positive early breast cancer concluded that, despite encouraging results from DESTINY-Breast011, current evidence remains insufficient to support upfront neoadjuvant trastuzumab deruxtecan as a standard-of-care option 42142430May. In metastatic breast cancer, another study evaluated discordance between HER2 reassessment methods (HercepTest and 4B5) in the context of HER2-low disease and trastuzumab deruxtecan eligibility 42329461Jun. A case report in non-small cell lung carcinoma with HER2 exon 20 insertion described successful trastuzumab deruxtecan rechallenge after early detection and management of interstitial lung disease, with subsequent tumor regression and no recurrence of ILD 41192915Nov.

What Changes, What Holds

1. Early clinical testing now extends trastuzumab rezetecan into HER2-expressing gastric, gastroesophageal junction, and colorectal cancer
NEW DIRECTION The phase I work broadens the entity from a general HER2-targeted ADC concept into an agent with direct human testing across advanced gastrointestinal malignancies, which the Overview had only framed as an active area of evaluation. It does not overturn the baseline mechanism or rationale, but it does make the clinical development status more concrete and tumor-specific. 41779980Mar

2. trastuzumab deruxtecan sequencing remains unsettled, but that uncertainty does not alter trastuzumab rezetecan’s baseline role
REINFORCES The surrounding trastuzumab deruxtecan studies mainly sharpen the broader HER2-ADC landscape by showing that prior therapy, including earlier ADC exposure or checkpoint inhibition, can matter for later treatment outcomes. That context supports the Overview’s point that sequencing and resistance are incompletely defined, but it does not add a new role for trastuzumab rezetecan or contradict its established description. 41980521Apr41789591Mar

3. Practical handling and safety surveillance are becoming part of HER2-ADC use, but they do not change trastuzumab rezetecan’s core account
METHOD The stability and pharmacovigilance papers concern how related HER2-directed ADCs are stored, monitored, and compared in practice, rather than what trastuzumab rezetecan is or does. They strengthen the sense that this drug class now requires operational and postmarketing infrastructure, yet they leave the baseline mechanism and development narrative intact. 42009233Apr42379740Jun

4. Upfront and biomarker-assessment questions around trastuzumab deruxtecan show that HER2-ADC adoption is still being defined, not settled
REINFORCES The commentary, receptor-discordance analysis, and rechallenge case all sit within the same unresolved clinical space the Overview already describes: optimal use, eligibility, and toxicity management for HER2-targeted ADCs remain in flux. These reports do not establish a new role for trastuzumab rezetecan, but they do underscore that the field’s practical boundaries are still being negotiated. 42142430May42329461Jun41192915Nov

Overview update candidates: early clinical testing in HER2-expressing gastric; gastroesophageal junction; and colorectal cancer.